High-density lipoproteins: the guardian angel of the cell membrane
Tóm tắt
High-density lipoproteins (HDL) plasma levels are inversely correlated with the risk of atherosclerosis and coronary heart disease. The protective effect of HDL has been related to their role in the cholesterol reverse transport and to their ability to inhibit oxidation of low-density lipoproteins (LDL). Several lines of evidence suggest that the protective effect of HDL is at least partially related to the enzyme paraoxonase (PON1), a calcium-dependent esterase associated with the HDL surface. It has been hypothesised that PON1 may have two independent antiatherogenic roles: (a) by preventing the accumulation of oxidised lipids from oxidised lipoproteins (LDL and HDL) and thereby inhibiting the atherogenic and inflammatory response induced by lipid peroxidation products; (b) by detoxifying homocysteine thiolactone (HTL), a toxic metabolite of homocysteine. Recently, it has been reported that HDL-associated PON1 could also play a regulatory role in HDL binding to cell membranes and in HDL-mediated cholesterol efflux in macrophages. Several papers have reported that HDL are also able to protect and/or repair oxidative damage of cell membranes and we have recently demonstrated that the protective role of HDL is related to PON1 activity.
Tài liệu tham khảo
Calvert GD, Abbey M (1985) Plasma lipoproteins, apolipoproteins, and proteins concerned with lipid metabolism. Adv Clin Chem 24:217–298
Assmann G, Nofer JR (2003) Atheroprotective effects of high density lipoproteins. Annu Rev Med 54:321–341
Qiao Q, Gao W, Zhang L et al (2007) Metabolic syndrome and cardiovascular disease. Ann Clin Biochem 44:232–263
Ferretti G, Bacchetti T, Busni D et al (2004) Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. J Clin Endocrinol Metab 89:2957–2962
Quijada Z, Paoli M, Zerpa Y et al (2008) The triglyceride/HDL-cholesterol ratio as a marker of cardiovascular risk in obese children; association with traditional and emergent risk factors. Pediatr Diabetes 9:464–471
Genest J, McNamara J, Salem D, Schaefer E (1991) Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 67:1185–1189
Negre-Salvayre A, Dousset N, Ferretti G et al (2006) Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radic Biol Med 41:1031–1040
Navab M, Yu R, Gharavi N et al (2007) High-density lipoprotein: antioxidant and anti-inflammatory properties. Curr Atheroscler Rep 9:244–248
Yoshikawa M, Sakuma N, Hibino T et al (1997) HDL3 exerts more powerful anti-oxidative, protective effects against copper-catalyzed LDL oxidation than HDL2. Clin Biochem 30:221–225
Klimov AN, Gurevich VS, Nikiforova AA et al (1993) Antioxidative activity of high density lipoproteins in vivo. Atherosclerosis 100:13–18
Mackness MI, Arrol S, Abbott C, Durrington PN (1993) Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104:129–135
Mackness MI, Durrington PN (1995) HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 115:243–253
Watson AD, Berliner JA, Hama SY et al (1995) Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96:2882–2891
Aviram M, Rosenblat M (2005) Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipidol 16:393–399
Ferretti G, Bacchetti T, Moroni C et al (2005) Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab 90:1728–1733
Mackness MI, Harty D, Bhatnagar D et al (1991) Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 86:193–199
Ferretti G, Bacchetti T, Masciangelo S, Pallotta G (2008) Lipid peroxidation in hemodialysis patients: effect of vitamin C supplementation. Clin Biochem 41:381–386
Ayub A, Mackness MI, Arrol S et al (1999) Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 19:330–335
Ferretti G, Bacchetti T, Principi F et al (2005) Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity. Mult Scler 11:677–682
Shih DM, Gu L, Xia YR et al (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394:284–287
Tward A, Xia YR, Wang XP et al (2002) Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 106:484–490
van Himbergen TM, van der Schouw YT, Voorbij HA et al (2008) Paraoxonase (PON1) and the risk for coronary heart disease and myocardial infarction in a general population of Dutch women. Atherosclerosis 199:408–414
Sentürk T, Sarandöl E, Güllülü S et al (2008) Association between paraoxonase 1 activity and severity of coronary artery disease in patients with acute coronary syndromes. Acta Cardiol 63:361–367
Klimov AN, Kozhevnikova KA, Kuzmin AA et al (2001) On the ability of high density lipoproteins to remove phospholipid peroxidation products from erythrocyte membranes. Biochemistry (Mosc) 66:300–304
Ferretti G, Bacchetti T, Moroni C et al (2003) Copper-induced oxidative damage on astrocytes: protective effect exerted by human high density lipoproteins. Biochim Biophys Acta 1635:48–54
Rosenblat M, Vaya J, Shih D, Aviram M (2005) Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis 179:69–77
Efrat M, Aviram M (2008) Macrophage paraoxonase 1 (PON1) binding sites. Biochem Biophys Res Commun 376:105–110
Bowry VW, Stanley KK, Stocker R (2002) High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci U S A 89:10316–10320
Jakubowski H (2000) Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem 275:3957–3962
Jakubowski H (2002) Homocysteine is a protein amino acid in humans. Implications for homocysteine-linked disease. J Biol Chem 277:30425–30428
Ferretti G, Bacchetti T, Moroni C et al (2004) Effect of homocysteinylation of low density lipoproteins on lipid peroxidation of human endothelial cells. J Cell Biochem 92:351–360